Did you mean 90 90 0?
Displaying drugs 1301 - 1325 of 1906 in total
CTB001
CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.
Investigational
PNT001
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
TUM012
TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)
Investigational
Gontivimab
Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Investigational
Alvespimycin
Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic...
Investigational
Matched Description: … Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. …
6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one
Experimental
Matched Iupac: … 3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1,4(9),5,7,10,15,17,19,21 …
Tebotelimab
Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
Investigational
Ponsegromab
Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With Heart Failure).
Investigational
Mavelertinib
Mavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).
Investigational
XMMME-001-RTA
Investigational
CVnCoV
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
AER001
AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.
Investigational
trans NV-04
trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Investigational
MAHDL01
MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.
Investigational
DAR-0100A
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
GTA002
Investigational
GDX012
Investigational
FCR001
FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational
Giroctocogene fitelparvovec
Giroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
Investigational
Ivuxolimab
Ivuxolimab is under investigation in clinical trial NCT02554812 (A Study of Avelumab in Combination With Other Cancer Immunotherapies in Advanced Malignancies (JAVELIN Medley)).
Investigational
FINLAY-FR-1
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute . It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and...
Investigational
M0002
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Displaying drugs 1301 - 1325 of 1906 in total